Oclacitinib (PF-03394197) is a potent JAK inhibitor with IC50 of 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
Oclacitinib (PF-03394197) does not significantly inhibit a panel of 38 other kinases when tested at 1 uM.
Oclacitinib (PF-03394197) inhibits IL-2, IL-4, IL-6, IL-13, and IL-31 with IC50's ranging from 36 to 249 nM, much less potent against erythropoietin and GM-CSF.
Oclacitinib (PF-03394197) inhibited JAK1-dependent cytokine receptor complexes involved in inflammation and pruritus, common clinical signs in canine allergic skin disease.
